Featured Research

from universities, journals, and other organizations

Hopkins Researchers Discover Key Target In Molecular Pathway That Initiates Colon Cancer

Date:
September 7, 1998
Source:
Johns Hopkins Medical Institutions
Summary:
In the latest of a series of discoveries about colon cancer genes, researchers at the Johns Hopkins Oncology Center and the Howard Hughes Medical Institute have discovered a connection between two of them, APC and c-MYC, that conspires to initiate almost all colon cancers.

In the latest of a series of discoveries about colon cancer genes, researchers at the Johns Hopkins Oncology Center and the Howard Hughes Medical Institute have discovered a connection between two of them, APC and c-MYC, that conspires to initiate almost all colon cancers. Their findings are reported in the September 4, 1998, issue of SCIENCE.

The APC tumor suppressor gene, which acts like a brake on cell growth, loses that ability when mutated. The c-MYC gene has long been known as an oncogene, a type of gene that promotes cancer cell growth. Now, Hopkins scientists Bert Vogelstein, M.D., and Kenneth W. Kinzler, Ph.D., have found that the mutated APC gene controls the expression of c-MYC activation. APC was first identified and linked to colon cancer in 1991 by research teams including those led by Vogelstein and Kinzler.

Every person carries the c-MYC oncogene, but it remains under control in the colon until APC inactivation awakens it, generating the distinctive uncontrolled cell growth that mark cancers. "Cancer is like a car with the accelerator pushed to the floor and failing brakes," says Vogelstein, professor of oncology at Hopkins and a Hughes scholar.

"In this case, c-MYC is the accelerator and APC is the failed brakes," he explains. When suppressor genes, like APC, malfunction either through heredity or as a result of exposure to carcinogens, cells get signals to continue multiplying until they are out of control. "Now we know that in colon cancer a mutated APC gene signals to c-MYC," Vogelstein says.

The new findings about the APC pathway and how it functions may suggest potential new drug strategies that could prevent colon cancer by blocking the signal that activates c-MYC, says Kinzler, associate professor of oncology and director of the study. "Just eight years ago, we didn't even know about APC mutations. Now, we know this type of mutation is one of the earliest genetic changes in most colon cancers, and we know what it does to c-MYC. It's like a jigsaw puzzle. We have identified individual pieces of the cancer puzzle and now we can begin to put them together to see the whole picture of how they work together to cause cancer," Kinzler says. Colon cancer, among the most common cancers in both men and women, this year will strike more than 131,000 Americans. Some 56,500 individuals will die of it.

In addition to Vogelstein and Kinzler, other research participants included Tong-Chuan He, M.D., Ph.D., Andrew B. Sparks, Ph.D., Carlo Rago, B.S., Heiko Hermeking, Ph.D., Leigh Zawel, Ph.D., Luis T. Da Costa, M.S., and Patrice J. Morin, Ph.D. The study was funded by the National Institutes of Health.

###

Under a licensing agreement between the Johns Hopkins University and Genzyme, SAGE technology, which was used this study, is licensed to Genzyme for commercial purposes. Kenneth W. Kinzler, Ph.D., and Bert Vogelstein, M.D., are entitled to a share of the royalty received by the University from sales of the licensed technology. The SAGE technology is freely available to academia for research purposes. Kinzler and Vogelstein are consultants to Genzyme. The University and the researchers own Genzyme stock, which is subject to certain restrictions under University policy. The terms of this arrangement are being managed by the University in accordance with its conflict of interest policies.


Story Source:

The above story is based on materials provided by Johns Hopkins Medical Institutions. Note: Materials may be edited for content and length.


Cite This Page:

Johns Hopkins Medical Institutions. "Hopkins Researchers Discover Key Target In Molecular Pathway That Initiates Colon Cancer." ScienceDaily. ScienceDaily, 7 September 1998. <www.sciencedaily.com/releases/1998/09/980907115538.htm>.
Johns Hopkins Medical Institutions. (1998, September 7). Hopkins Researchers Discover Key Target In Molecular Pathway That Initiates Colon Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/1998/09/980907115538.htm
Johns Hopkins Medical Institutions. "Hopkins Researchers Discover Key Target In Molecular Pathway That Initiates Colon Cancer." ScienceDaily. www.sciencedaily.com/releases/1998/09/980907115538.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins